Many risk factors exist for chemotherapy-induced nausea and vomiting (CINV). This study utilized a multivariate projection technique to identify which risk factors were predictive of CINV in clinical practice. A single-centre, prospective, observational study was conducted from January 2007~July 2010 in Singapore. Patients were on highly (HECs) and moderately emetogenic chemotherapies with/with...

PURPOSE Assess the surgical complications of primary tumor resection in stage IV colon cancer patients previously treated with neoadjuvant chemotherapy. METHODS Between July 2001 and September 2010, 67 consecutive patients received preoperative chemotherapy. Clinical and surgical complications were obtained from the medical records. This study was retrospective in design. RESULTS All patien...

BACKGROUND 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a ...

For the last four decades, synthesis and testing of potentially active drugs (e.g., antimetabolites) have focused on structural modification of existing metabolites as precursors of DNA and RNA synthesis. In recent years, the focus has shifted to synthesis of target-specific agents. Thus, the current emphasis of drug development is directed at inhibiting specific target(s) expressed preferentia...

© TOUCH MEDICAL MEDIA 2013 93 A satellite symposium, chaired by Eric Van Cutsem and Josep Tabernero, was held on the 3rd July 2013 at the European Society for Medical Oncology (ESMO) 15th World Congress of Gastrointestinal Cancer in Barcelona to discuss the oral fluoropyrimidine S-1. Systemic chemotherapy is the standard treatment for unresectable, advanced or recurrent gastrointestinal (GI) ca...

P.S. is a 53-year-old female patient with stage IIB breast cancer. In November 2000, she received Adriamycin (Pfizer Inc., New York, NY) and Cytoxan (Bristol-Myers Squibb, New York, NY), along with Herceptin (Genentech, Inc., South San Francisco, CA), as part of a clinical trial. In July 2002, the patient was found to have a left supraclavicular axillary recurrence. Because of this recurrence, ...

BACKGROUND Hyopkalemia is a listed toxicity in the capecitabine (Xeloda(R); Roche, Nutley, NJ) package insert. However, the incidence and severity of this toxicity is not known. METHODS We performed a retrospective evaluation of hypokalemia in 77 patients, who received capecitabine for gastrointestinal malignancies between April 2002 and November 2004. Hypokalemia was defined as K(+) level <3...

In BrIef Non-adherence can have profound clinical consequences in the treatment of chronic diseases— especially cancer. Medication non-adherence in patients with cancer is a growing concern today due to the increasing availability of new oral agents. Many factors contribute to patient non-adherence to treatment regimens. Understanding the potential barriers and factors that affect patient adher...

A large proportion of gastric cardia adenocarcinoma (GCA) present initially in an advanced stage in China. Skin metastasis of primary GCA rarely occurs and the incidence of it is still unclear yet. Here we report one case of skin metastasis from GCA in a 58-year-old male patient who underwent gastric cardia resection in 2002 and did not undergo chemotherapy. However, he was diagnosed with anast...

PURPOSE To determine the maximum tolerated dose (MTD) of continuous oral capecitabine plus oxaliplatin and pre-operative pelvic radiotherapy (XELOX-RT). PATIENTS AND METHODS Patients with clinically unresectable rectal cancer or for whom resection with histologically clear (R0) surgical margins was unlikely received continuous capecitabine (500-825 mg/m2 twice daily, 7 days/week), oxaliplatin...